Gilder Gagnon Howe & Co. LLC Lowers Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Gilder Gagnon Howe & Co. LLC reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 3.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 162,023 shares of the company’s stock after selling 6,589 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Hims & Hers Health were worth $3,918,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. SlateStone Wealth LLC grew its stake in Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after buying an additional 413 shares during the period. Blume Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after purchasing an additional 628 shares during the period. Harbour Investments Inc. increased its holdings in Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after purchasing an additional 833 shares in the last quarter. Finally, Stonekeep Investments LLC raised its position in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after purchasing an additional 882 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Melissa Baird sold 67,687 shares of the business’s stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $44.71, for a total transaction of $3,026,285.77. Following the completion of the transaction, the chief operating officer now directly owns 706,872 shares of the company’s stock, valued at $31,604,247.12. The trade was a 8.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $35.22, for a total transaction of $3,522,000.00. Following the completion of the sale, the chief executive officer now owns 27,918 shares in the company, valued at $983,271.96. The trade was a 78.18 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 712,998 shares of company stock valued at $27,992,450. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

HIMS opened at $28.10 on Friday. The company has a market capitalization of $6.24 billion, a P/E ratio of 63.87 and a beta of 1.65. The company has a 50-day moving average of $34.24 and a 200-day moving average of $30.99. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of a number of recent research reports. Citigroup lowered their target price on Hims & Hers Health from $27.00 to $25.00 and set a “sell” rating for the company in a research note on Friday. Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Truist Financial decreased their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a research note on Thursday, April 10th. Finally, Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $38.08.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.